Healios K.K.   Report issue

For profit Phase 3
Founded: Tokyo Japan (2011)

Organization Overview

First Clinical Trial
2014
NCT01952847
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Healios K.K. | Healios Oncology Nutrition

Active Ingredients

Drugs in Phase 3 Trials (2)

allogeneic hematopoietic stem cells (Hemacord) (2 trials)

l-glutamine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Esophagitis (Phase 3)

Mucositis (Phase 3)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Stroke (Phase 3)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2